This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Ultragenyx Faces Class Action Lawsuit
Business class action lawsuit

Ultragenyx Faces Class Action Lawsuit

Analysis based on 50 articles · First reported Feb 09, 2026 · Last updated Mar 07, 2026

Sentiment
-20
Attention
2
Articles
50
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of a class action lawsuit against Ultragenyx, as it suggests potential financial liabilities and a loss of investor confidence. This event could lead to a decrease in Ultragenyx's stock price.

Biotechnology Legal Services
Event Summary

Rosen Law Firm has announced a class action lawsuit against Ultragenyx, reminding investors of the April 6, 2026 lead plaintiff deadline. The lawsuit alleges that Ultragenyx made materially false and misleading statements to investors between August 3, 2023, and December 26, 2025, concerning its Phase III Orbit and Cosmic Studies for setrusumab (UX 143) in patients with Osteogenesis Imperfecta (OI). Specifically, the lawsuit claims that Ultragenyx expressed confidence in setrusumab's ability to decrease annualized fracture rates and the study designs' ability to demonstrate this, while allegedly concealing that increased bone density did not correlate with reduced fracture rates and that the studies were less likely to prove such a link. Investors who purchased Ultragenyx common stock during this period may be entitled to compensation.

Key Actions
100 Rosen Law Firm filed a class action lawsuit Ultragenyx
90 Ultragenyx made false and/or misleading statements
90 Ultragenyx allegedly disseminated false and misleading statements
Entities Involved
stock
Ultragenyx
Ultragenyx is facing a class action lawsuit alleging that it made materially false and misleading statements regarding its Phase III Orbit and Cosmic Studies for setrusumab. This could lead to financial penalties and reputational damage for the company.
Importance 100 Sentiment -50
priv
Rosen Law Firm
Rosen Law Firm is initiating and representing investors in a class action lawsuit against Ultragenyx, seeking compensation for shareholders who purchased stock during the Class Period. This action enhances the firm's reputation and business.
Importance 90 Sentiment 70
per
Philip Kim
Philip Kim, an attorney at Rosen Law Firm, is actively involved in the Ultragenyx class action lawsuit, serving as a contact for investors interested in joining the action.
Importance 50 Sentiment 60
per
Lawrence Rosen
Lawrence Rosen, a founding partner of Rosen Law Firm, is highlighted for his firm's success in securities class actions, including the Ultragenyx case, reinforcing his professional standing.
Importance 50 Sentiment 60
Relationships
Philip Kim related ↔ Rosen Law Firm
Lawrence Rosen related ↔ Rosen Law Firm
Ultragenyx related ↔ Rosen Law Firm
Rosen Law Firm related ↔ Ultragenyx
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.